Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jaguar Health, Inc. (NASDAQ: JAGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its capital markets activity and material agreements. Jaguar is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals, and its filings provide insight into how it finances and supports these programs.
Recent Form 8-K filings describe a range of transactions, including secured and unsecured promissory notes, royalty interest agreements and amendments, PIPE financings involving Series N Perpetual Preferred Stock and common stock with pre-funded warrants, and privately negotiated exchanges of preferred stock for common shares and pre-funded warrants. Other 8-Ks outline at-the-market offering amendments, conditional approval-related developments for Canalevia-CA1, and note purchase agreements backed by deposit account control arrangements and subsidiary guarantees.
Jaguar’s proxy materials, such as definitive proxy statements on Schedule 14A, detail stockholder proposals to approve share issuances under Nasdaq Listing Rule 5635(d), including common stock issuable upon exchange of Series L, Series M, and Series N preferred stock and upon conversion of certain convertible promissory notes and related warrants. These documents also explain voting rights, voting caps for preferred series, and the structure of special and annual meetings.
On this page, users can review Jaguar’s 10-K and 10-Q reports (when available) for broader business and risk disclosures, while Form 4 and related ownership filings provide visibility into insider equity transactions. Stock Titan enhances these filings with AI-powered summaries that highlight key terms in complex documents, such as interest rates, maturity dates, collateral arrangements, voting provisions, and share issuance conditions. Real-time updates from EDGAR ensure that new Jaguar Health filings, including 8-Ks announcing material events, are quickly accessible with plain-language explanations.
Jaguar Health, Inc. reported that Nasdaq notified the company on March 5, 2026 that it is no longer in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price of its common stock has closed below $1.00 per share for the previous 30 consecutive business days.
Nasdaq also stated the company is not eligible for a standard compliance period because it effected one or more reverse stock splits over the prior two years with a cumulative ratio of at least 250-to-1. Unless Jaguar Health requests an appeal before a Nasdaq Hearings Panel by March 12, 2026, its securities would be scheduled for delisting.
Jaguar Health intends to timely request this appeal, which would automatically stay any further suspension or delisting action at least until the hearing process is concluded. The company cautions there can be no assurance that the Panel will grant continued listing or that it will regain and maintain compliance with Nasdaq’s standards.
Jaguar Health, Inc. detailed the terms of a special one-time dividend of its new Series O Convertible Preferred Stock, giving one-tenth of a Series O share for each common share and for common shares issuable under Eligible Warrants outstanding as of the
Jaguar Health declared a special one-time stock dividend of Series O Convertible Preferred Stock, granting one-tenth of one Series O share for each share of common stock and for Eligible Warrants covering 2,400,765 common shares held on the March 2, 2026 record date. The dividend is expected to be paid on March 4, 2026. The Series O Preferred Stock is non-transferable, pays no dividends, has minimal liquidation preference, and carries almost no voting rights, but will convert into common stock at the company’s election or automatically on December 31, 2026 based on a market-linked conversion price, subject to a 19.99% beneficial ownership cap per holder. Jaguar’s risk disclosures highlight that full conversion of the Series O Preferred Stock and potential future exchanges of approximately $30 million of debt into common stock could result in substantial dilution and pressure on the share price. The company also warns of ongoing risks to maintaining its Nasdaq listing following multiple reverse stock splits and evolving listing standards.
Lincoln Alternative Strategies LLC has filed an amended Schedule 13G reporting that it no longer beneficially owns any common stock of Jaguar Health, Inc. The firm now reports ownership of 0 shares, representing 0% of the outstanding common stock as of the event date January 12, 2026.
The filing states Lincoln Alternative Strategies has no sole or shared voting or dispositive power over Jaguar Health shares and confirms its holdings are below the 5% reporting threshold. It also certifies that any securities previously held were not acquired or held for the purpose of influencing control of Jaguar Health.
Jaguar Health entered a series of privately negotiated exchange agreements with Iliad Research and Trading and Streeterville Capital, converting royalty and preferred stock obligations into pre-funded common stock warrants. The company issued pre-funded warrants to Iliad to purchase 1,553,844 shares in exchange for a
Jaguar Health, Inc. reported an equity compensation award to executive Steven R. King, who serves as Chief of Sustainable Supply, Ethnobotanical Research and Intellectual Property and Secretary. On December 11, 2025, he was granted 11,740 shares of common stock, bringing his directly held common stock to 11,885 shares. These shares reflect restricted stock units granted under the company’s 2014 Stock Incentive Plan and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date.
On the same date, King also received a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests in equal monthly installments over 12 months from the grant date, contingent on his continued employment. Both the restricted stock units and options were approved by the board of directors as part of the company’s stock incentive program, and were reported as directly owned.
Jaguar Health, Inc. reported an equity compensation grant to Chief Executive Officer and President Lisa A. Conte, who is also a director. On December 11, 2025, she received 28,592 restricted stock units of common stock at a price of $0, increasing her directly owned common shares to 29,258. Each unit represents one share and will vest on December 11, 2026, with shares delivered on that date.
On the same date, she was granted stock options for 28,592 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. These options vest ratably on a monthly basis over 12 months from the grant date, contingent on her continued employment, and were issued under the company’s 2014 Stock Incentive Plan.
Jaguar Health, Inc. reported an equity award to officer Jonathan S. Wolin, who serves as Chief of Staff, Chief Compliance Officer and General Counsel. On December 11, 2025, he received 11,740 shares of common stock in the form of restricted stock units at a price of $0, granted under the company’s 2014 Stock Incentive Plan. These restricted stock units each represent one share of voting common stock and are scheduled to vest on December 11, 2026, with shares delivered on the vesting date as provided in the grant notice.
On the same date, he was also granted a stock option for 11,740 shares of common stock with an exercise price of $1.44 per share, expiring on December 11, 2035. The option vests ratably on a monthly basis over 12 months from the grant date, contingent on his continued employment. After these grants, he directly beneficially owned 11,938 shares of common stock and options covering 11,740 shares.
Jaguar Health, through its subsidiary Napo Pharmaceuticals, entered a major U.S. license and supply deal for its Mytesi and Canalevia products with Woodward Specialty, an affiliate of Future Pak. Napo granted the licensee exclusive rights to commercialize these products in the United States and will supply finished product under a separate supply agreement.
In return, Napo receives an upfront payment of $18 million, consisting of $16 million paid on January 12, 2026 and a $2 million holdback contingent on specified conditions by the six‑month anniversary of that date, plus potential milestone payments of up to $17 million tied to defined events. Future Pak provides limited guarantees of the licensee’s milestone and supply payment obligations. Starting after the fifth anniversary of the effective date, if Napo secures U.S. FDA approval for additional Mytesi indications and complies with the agreement, it has a unilateral option to buy back all licensed rights by making a contractually defined payment.
Jaguar Health, Inc. filed an amended current report to correct execution, closing, and report dates related to a recent financing agreement, and to replace prior exhibits with corrected versions. On January 6, 2026, the company entered into securities purchase agreements with two accredited investors and issued $350,000 aggregate principal amount of unsecured promissory notes, bearing interest at 6% per annum and maturing one month after issuance. The company may prepay the notes without penalty and plans to use the proceeds for working capital and general corporate purposes. As an inducement, the investors received warrants to purchase up to 350,000 shares of common stock at an initial exercise price of $1.00 per share, exercisable immediately and expiring after up to five years or upon certain corporate events. The securities were sold in a private placement relying on exemptions under Section 4(a)(2) and Rule 506 of Regulation D.